Key result
Intensive GDMT titration in elderly HFrEF patients proves feasible, with ~8% experiencing acute kidney injury.
Why the study?
Elderly patients with HFrEF often face therapeutic inertia and more adverse events, creating uncertainty about the efficacy and safety of intensive titration programs for GDMT.
Does an intensive titration program improve the prescription rate of quadruple GDMT at 3 months in HFrEF patients aged ≥ 75 years?
Observational
No
Does an intensive titration program improve the prescription rate of quadruple GDMT at 3 months in HFrEF patients aged ≥ 75 years?
An intensive titration program for quadruple guideline-directed medical therapy in elderly HFrEF patients appears feasible but requires close monitoring for hypotension and acute kidney injury.
Answers are grounded in this paper and cite their sources.
Supports intensive GDMT titration in elderly HFrEF; extends evidence to a population with therapeutic inertia and higher adverse-event risk.
Background: Guideline-directed medical therapy (GDMT) for heart failure (HF) with reduced ejection fraction (HFrEF) relies on quadruple therapy, including beta-blockers (BB), angiotensin receptor-neprilysin inhibitors (ARNi), mineralocorticoid receptor antagonists (MRA), and sodium-glucose cotransporter 2 inhibitors (SGLT2i). Elderly patients with HF represent a high-risk population and often face therapeutic inertia but also more adverse events. We aimed to assess the efficacy and safety of an intensive titration program (ITP) for elderly HFrEF patients. Methods: We conducted a prospective, single-center, observational study including HFrEF patients aged ≥ 75 years managed with an ITP between January 2024 and February 2025. The primary outcome was the prescription rate of quadruple GDMT at 3 months, irrespective of dose. Secondary outcomes included prescription of quadruple therapy at ≥ 50% of GDMT target doses and identification of predictors of limited implementation. Safety outcomes included adverse events occurring during titration and within 3 months after completion. These improvements were associated with short-term clinical and biological benefits (NT-proBNP reduction, improved left ventricular ejection fraction). Reported adverse events included symptomatic hypotension (8% with treatment discontinuation) and acute kidney injury (8 % requiring hospitalization). Older age and chronic kidney disease were associated with limited initiation of quadruple therapy. Conclusion: An intensive titration program for HFrEF therapy appears feasible and relatively safe in elderly patients.
No takes yet. Share an insight, caveat, or question.
Benezech et al. (2026) conducted an observational in Heart failure with reduced ejection fraction (HFrEF). Intensive titration program (ITP) was evaluated on Prescription rate of quadruple GDMT at 3 months, irrespective of dose (p=<0.05). An intensive titration program for elderly HFrEF patients was feasible and relatively safe, with 8% symptomatic hypotension and 8% acute kidney injury requiring hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: